News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioTime (BTX) Subsidiary Asterias Biotherapeutics Raises $13.0 Million In Equity Financing



6/17/2014 10:14:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”), has raised $12.5 million through the sale of 5,000,000 BioTime common shares held by Asterias and the issuance of warrants to purchase 5,000,000 shares of Asterias Series B Common Stock. The majority of the funds raised through this privately negotiated transaction will be used to finance Asterias’ product development programs, including AST-OPC1 for the treatment of spinal cord injury, and AST-VAC2, which is being developed as an immunotherapy for non-small cell lung cancer. The investors included BioTime’s largest shareholder and a trust established by another long-term BioTime shareholder. In addition, as reported earlier today, Pedro Lichtinger, Asterias’ President and Chief Executive Officer, has invested $0.5 million directly into Asterias through the purchase of 200,000 shares of Asterias Series B Common Stock.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES